mynth
← DATABASE
08/2012MajorityLBO

BC Partners takes majority stake in Aenova Group

GERMANY Life Sciences / Pharma & Biotech / CDMO EV €300–700M

Context

BC Partners have signed a definitive agreement to acquire a majority stake in the Aenova Group from the European private equity firm Bridgepoint. This secondary LBO marks the end of Bridgepoint’s ownership period, which began in 2005, during which Aenova was transformed into one of Europe’s leading CDMOs. The current management team, led by CEO Heiner Hoppmann and CFO Frank Elsen, will remain at the helm to lead the next phase of the company's development. The strategic rationale for the acquisition is focused on leveraging Aenova’s superb market positioning to drive both organic and inorganic growth. BC Partners intends to utilize the group as a platform for further acquisitions to broaden its service range and enhance its competitive standing in international markets. For Aenova, the partnership with BC Partners provides the necessary capital to expand its "customer-centric" strategy and invest in innovative manufacturing technologies.

Aenova Group, which reported an EBITDA margin of [members only] in 2012, is valued in this transaction at an EV/EBITDA multiple of 5x–12x.

-> Deep-dive in Healthcare & Pharma market trends

Target

The Aenova Group is a leading global contract development and manufacturing organization (CDMO) serving the pharmaceutical and healthcare industries. Headquartered in Starnberg, Germany, the company operates as a comprehensive "one-stop shop" for the development, production, and packaging of a vast array of drug products. Its technical capabilities span all common dosage forms (including solid, semi-solid, liquid, sterile, and non-sterile applications) across both human and animal health. The group is particularly noted for its expertise in handling diverse active ingredient classes, ranging from standard pharmaceuticals to specialized food supplements, with high-containment capabilities (OEB 1 to 5). Its business model focuses on providing end-to-end supply chain services to global pharma companies, supported by a network of 14 specialized manufacturing sites across Europe and the USA. By combining operational excellence in conventional manufacturing with advanced technology platforms, Aenova addresses the complex regulatory and technical requirements of the modern pharmaceutical market, positioning itself as one of the ten largest CDMOs worldwide.

Ent. Value

€300–700M

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

5x–12x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2012
€250–500M
€50–100M
[members only]
2011
€250–500M
€50–100M
[members only]

Other operations with Aenova Group

Other operations with Aenova Group
DateAcquirerTargetCountrySector
04/2024KÜHNE HOLDINGAENOVA GROUPGERMANYCDMO

Other operations with BC Partners

Other operations with BC Partners
DateAcquirerTargetCountrySector
06/2018BC PARTNERSFORNO D’ASOLOITALYBakery / Pastry
10/2017BC PARTNERSCERAMTECGERMANYGlass & Ceramics
05/2017BC PARTNERSDENTALPROITALYDental Centers
07/2016BC PARTNERS / PSP INVESTMENTSKETERISRAELHome & DIY
11/2015BC PARTNERSCIGIERREITALYRestaurants / Chains
07/2015BC PARTNERSCÔTE RESTAURANTSUNITED KINGDOMRestaurants / Chains
06/2015BC PARTNERSPHARMATHENGREECECDMO
12/2014BC PARTNERS / CDPQ - CAISSE DE DEPOT ET PLACEMENT DU QUEBECPETSMARTUNITED STATESPet Care
06/2013BC PARTNERSANTELLIQFRANCEAnimal Health
09/2005BC PARTNERSFITNESS FIRSTUNITED KINGDOMHospitality

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
10/2013ARDIANLABORATOIRES ANIOSFRANCEMedical Consumables
07/2013CHARTERHOUSEDOC GENERICIITALYGenerics / Labs
06/2013EURAZEOPÉTERS SURGICALFRANCEMedical Consumables
06/2013BC PARTNERSANTELLIQFRANCEAnimal Health
01/2013ELITECH GROUPVITAL DIAGNOSTICSUNITED STATESDiagnostic Equipment
05/2011AZULIS CAPITAL / BNP PARIBAS DEVELOPPEMENT / GALIALAGARRIGUEFRANCEImplants & Prosthetics
09/2010SPARRING CAPITALIMV TECHNOLOGIESFRANCER&D Biotech
09/2009THE CARLYLE GROUPMARLE GROUPFRANCEImplants & Prosthetics
04/2007ASTORGETHYPHARMFRANCEPharma & Biotech
01/2006EDMOND DE ROTHSCHILD CAPITAL PARTNERSACTEONFRANCEMedical Devices

REFERENCES

Valuation range: EV €300–700M

Revenue range: €250–500M

EBITDA range: €50–100M

EV/Revenue range: 1x - 3x

EV/EBITDA range: 5x - 12x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Aenova Group by BC Partners are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Aenova Group, a German company specialised in Pharma & Biotech, by BC Partners in 2012, structured as a leveraged buyout (LBO). Ownership has since evolved, leading to a subsequent transaction with Kühne Holding in April 2024 (see the dedicated deal page for details).

How was the acquisition of Aenova Group by BC Partners valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €300–700M band, its EV/EBITDA multiple within the 5x - 12x range, and its EV/revenue multiple within the 1x - 3x range. Exact figures are available to members.

What were Aenova Group’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Aenova Group generated annual revenue estimated in the €250–500M range and EBITDA in the €50–100M bracket (FY 2012). Detailed financial figures are available to members.

What sources support the information on this transaction?

Transaction data and operational intelligence were compiled from independent financial press reporting by specialized M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.